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Abstract: Infections related to Aspergillus species have emerged to become an important 
focus in infectious diseases, as a result of the increasing use of immunosuppressive agents 
and high fatality associated with invasive aspergillosis. However, laboratory diagnosis of 
Aspergillus infections remains difficult. In this study, by comparing the metabolomic 
profiles of the culture supernatants of 30 strains of six pathogenic Aspergillus species  
(A. fumigatus, A. flavus, A. niger, A. terreus, A. nomius and A. tamarii) and 31 strains of  
10 non-Aspergillus fungi, eight compounds present in all strains of the six Aspergillus 
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species but not in any strain of the non-Aspergillus fungi were observed. One of the  
eight compounds, Leu–Glu–Leu–Glu, is a novel tetrapeptide and represents the first linear 
tetrapeptide observed in Aspergillus species, which we propose to be named aspergitide. 
Two other closely related Aspergillus-specific compounds, hydroxy-(sulfooxy)benzoic acid 
and (sulfooxy)benzoic acid, may possess anti-inflammatory properties, as 2-(sulfooxy)benzoic 
acid possesses a structure similar to those of aspirin [2-(acetoxy)benzoic acid] and salicylic 
acid (2-hydroxybenzoic acid). Further studies to examine the potentials of these 
Aspergillus-specific compounds for laboratory diagnosis of aspergillosis are warranted and 
further experiments will reveal whether Leu–Glu–Leu–Glu, hydroxy-(sulfooxy)benzoic 
acid and (sulfooxy)benzoic acid are virulent factors of the pathogenic Aspergillus species. 
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1. Introduction 
In recent years, infections related to Aspergillus species have become an emerging focus of clinical 
microbiology and infectious disease as the number of patients infected with Aspergillus species rose 
dramatically. In immunocompetent and mildly immunocompromised hosts, Aspergillus species rarely 
cause serious illnesses, except for pulmonary aspergilloma in patients with pre-existing chronic lung 
diseases and, less commonly, chronic cavitary pulmonary aspergillosis, chronic fibrosing aspergillosis 
and chronic necrotizing aspergillosis [1–5]. On the other hand, invasive aspergillosis is one of the most 
important causes of morbidity and mortality in immunocompromised patients, such as those with 
hematological malignancies undergoing chemotherapy, hematopoietic stem cell and solid organ 
transplantation and HIV infection [1,6]. Among the known Aspergillus species, Aspergillus fumigatus 
is the most common species causing human infections in western countries, whereas Aspergillus flavus 
is as important as A. fumigatus in our locality and in other Asian countries, and is the second most 
common Aspergillus species associated with human infections in western countries [1,6]. Other Aspergillus 
species commonly associated with human infections include Aspergillus niger and Aspergillus terreus [1,6]. 
The successful management of invasive aspergillosis is hampered by difficulties in establishing 
timely and accurate diagnosis. The gold standard for making a diagnosis is to obtain a positive culture 
of A. fumigatus and to demonstrate histological evidence of mycelial invasion from tissue biopsy. Due to 
the very sick nature of these patients and often the presence of bleeding diathesis, tissue biopsy is often 
not possible or acceptable by patients. Although commercial kits for galactomannan antigen detection 
and our in-house developed Afmp1p and Afmp2p antigen detection assays are available for clinical use, 
the sensitivities of these tests are far from ideal [2–5,7]. Molecular tests such as PCR are also used for 
laboratory diagnosis, but such tests cannot distinguish among environmental contamination, colonization 
and genuine invasive infection [8,9]. 
Microbial metabolomics is a relatively new research field that involves the study of the unique 
chemical fingerprints of the metabolite profiles of microorganisms, and has been used for the 
characterization of a number of pathogenic microbes [10–13]. For example, urine metabolomic data 
can be used for the diagnosis of Streptococcus pneumoniae infections and urinary tract infections [14–16]. 
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We have also reported the application of metabolomics for identification of mitorubrinol yellow 
pigment in the pathogenic dimorphic fungus, Penicillium marneffei, and characterization of 
Tsukamurella and Aspergillus strains [17–19], as well as detection of specific metabolites in culture 
supernatant of Mycobacterium tuberculosis which may have important diagnostic applications [20]. 
Since our previous study showed that metabolomics profiling can be used to distinguish among 
different Aspergillus species [17], we hypothesize that there could be Aspergillus-specific novel 
extracellular metabolites that may be detected in blood and body fluids for laboratory diagnosis of 
invasive aspergillosis. In order to look for these potential biomarkers of invasive aspergillosis, we 
characterized the metabolomic profiles of the culture supernatants of Aspergillus species and other 
clinically important fungal species, using ultrahigh performance liquid chromatography-electrospray 
ionization-quadrupole time-of-flight mass spectrometry (UHPLC–ESI-Q-TOF-MS). Multi- and univariate 
statistical analyses of the metabolomic profiles were performed to identify Aspergillus-specific metabolites. 
2. Results 
2.1. Visual Inspection of Total Ion Chromatograms 
The metabolomes of culture supernatants of the 128 samples, including 30 samples of the 30 Aspergillus 
strains in duplicate and 34 samples from the 31 non-Aspergillus fungal strains (six samples were 
obtained from the mold and yeast forms of the three P. marneffei strains) in duplicate, were 
characterized and compared. UHPLC–ESI-Q-TOF-MS methods, operated in both positive and 
negative modes, for the analysis of different metabolites in fungal culture supernatant, were developed. 
Total ion chromatograms (TIC) from the Aspergillus strains shared considerable similarity and those of 
the same Aspergillus species showed high similarity, whereas significant differences were observed 
from the TICs of the different non-Aspergillus species. Representative examples of chromatograms 
from each species obtained in both positive and negative modes are shown in Figure 1A,B, respectively. 
2.2. Omics-Based Bioinformatics Analysis 
There were 32,849 molecular features (MFs) detected in positive electrospray ionization (ESI) 
mode and 39,303 MFs detected in negative ESI mode. All MFs were subjected to the Mass Profiler 
Professional (MPP) software for statistical analysis. After filtering by the MPP software, total of 2404 
MFs in positive mode and 1737 MFs in negative mode were obtained. Stepwise filtering procedure 
was used to identify significant MFs in Aspergillus strains and to reduce the dimensionality of data 
prior to principle component analysis (PCA) and partial least squares discriminant analysis (PLS-DA). 
To compare the metabolomes between Aspergillus and non-Aspergillus fungal strains, both uni- and 
multi-variate analyses were performed. Three-hundred-and-six features in positive mode and 44 features in 
negative mode were further subjected for volcano plot analysis. Using Student’s t-test with p-value <0.01 
and fold-change (FC) >16 to compare the Aspergillus and non-Aspergillus groups, the number of MFs was 
reduced to 287 features in positive mode and 42 features in negative mode after stepwise filtering for 
PCA and PLS-DA analyses. 
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Figure 1. Total ion chromatograms of Aspergillus species and other control fungal species 
used in this study. (A) Positive ionization mode; (B) Negative ionization mode. 
2.3. PCA and PLS-DA Modeling 
To compare the metabolomes between Aspergillus and non-Aspergillus strains, multivariate 
analysis was performed. In the positive ionization mode, PCA score plot showed that 48.18% of the 
total variance in the data was represented by the first two principal components (PCs), in which PC1 
explained 40.31% of the variance and PC2 explained 7.87% in the three-dimensional PCA score plots 
(Figure 2A). In the negative ionization mode, PCA score plot showed that 54.10% of the total variance 
in the data was represented by the first two PCs, in which PC1 explained 48.27% of the variance and 
PC2 explained 5.83% in three-dimensional PCA score plots, which gave a better clustering than the 
positive ionization mode (Figure 2B). All PCA score plots revealed that the Aspergillus strains were 
closely related to each other and can be distinguished from the non-Aspergillus strains, based on the 
first two principal components, where the Aspergillus strains were clearly separated from the  
non-Aspergillus strains along PC1. PCA loading plots for the respective MFs, which account for the 
separation between the Aspergillus and non-Aspergillus strains, were also generated in either positive 
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ionization mode (Figure 2C) or negative ionization mode (Figure 2D). MFs that showed statistically 
significance in the Aspergillus strains were extracted for further analysis. 
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Figure 2. PCA score plots and PCA loading plots of 128 fungal culture supernatant 
samples. PCA score plots for (A) positive ionization mode data and (B) negative ionization 
mode data; PCA loading plots of molecular features for (C) positive ionization mode data 
and (D) negative ionization mode data. 
In view of the significant separation achieved using PCA, supervised PLS-DA using t-score plots 
was employed to maximize the separation between the Aspergillus and non-Aspergillus strains, to find 
potential marker variables, to validate statistical model and to predict sample class membership. In both 
positive and negative ionization modes, sample classifications using the PLS-DA model achieved 
100% accuracy in both recognition and prediction abilities, indicating that the Aspergillus and  
non-Aspergillus strains were correctly classified during model training and cross-validation.  
Excellent separations of the Aspergillus and non-Aspergillus strains obtained by PLS-DA were shown 
in Figure 3. 
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Figure 3. PLS-DA t-score plots of 128 fungal culture supernatant samples. (A) Positive 
ionization mode; (B) negative ionization mode. 
2.4. Identification of Potential Biomarkers in Aspergillus Species 
Potential biomarkers in Aspergillus species were identified according to the elution order, MS/MS 
fragmentation pattern, molecular formula and database search. A total of eight potential biomarkers 
were identified (Tables 1 and A1). Box and whisker plots of the integral peak areas for all the eight 
metabolites were constructed (Figure 4). 
Table 1. Specific metabolites in culture supernatant of Aspergillus species. 
Compound m/z 
Retention 
Time (min) 
Ionization 
Mode 
Ion MS/MS Fragment Masses p Value a
Molecular 
Formula 
Putative Identity 
1 166.0724 1.86 Positive [M + H]+ 
107.0232, 124.0493, 149.0446, 
166.0712 
<0.001 C6H7N5O 7-Methylguanine 
2 166.0724 3.60 Positive [M + H]+ 
110.0327, 135.0292, 149.0441, 
166.0702 
<0.001 C6H7N5O 1-Methylguanine 
3 232.9775 6.20 Negative [M − H]− 96.9593, 109.0288, 153.0192, 
188.9861, 232.9775 
<0.001 C7H6O7S 
Hydroxy(sulfooxy) 
benzoic acid 
4 216.9822 6.80 Negative [M − H]− 79.9570, 93.0346, 96.9598, 
137.0245, 172.9911, 216.9816 
<0.001 C7H6O6S (sulfooxy)benzoic acid 
5 503.2749 9.98 Positive [M + H]+ 
96.0458, 114.0557, 131.0818, 
225.1232, 243.1329, 261.1452, 
503.2730 
<0.001 C22H38N4O9 Leu–Glu–Leu–Glu 
6 292.2645 19.55 Positive [M + H]+ 
74.0963, 203.1426, 219.1743, 
292.2633 
<0.001 C19H33NO No match 
7 352.2466 28.5 Positive [M + H]+ 
81.0189, 94.0269, 165.1127, 
194.1155, 210.1103 
<0.001 C20H33NO4 No match 
8 352.2466 28.8 Positive [M + H]+ 
81.0191, 94.0268, 165.1126, 
194.1156, 210.1105 
<0.001 C20H33NO4 No match 
a p value from ANOVA analysis. 
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Figure 4. Comparison of abundance of metabolites specific to the six Aspergillus species. 
Box-and-whisker plots of (A) 7-methylguanine; (B) 1-methylguanine; (C) hydroxyl(sulfooxy) 
benzoic acid; (D) (sulfooxy)benzoic acid; (E) Leu–Glu–Leu–Glu; (F) metabolite with 
protonated molecular ion of m/z 292.2645 eluted at 19.55 min; (G) metabolite with 
protonated molecular ion of m/z 352.2466 eluted at 28.5 min; (H) metabolite with 
protonated molecular ion of m/z 352.2466 eluted at 28.8 min. Boxes show first to third 
quartiles; whiskers show 5% and 95% percentiles; middle lines in boxes and numbers on 
the top of boxes indicate the median of the relative abundance of metabolite. 
Two metabolites (compounds 1 and 2 in Table 1), at retention time 1.86 and 3.60 min, with the 
same theoretical [M + H]+ of m/z 166.0724 and molecular formula of C6H7N5O, were identified as  
7-methylguanine and 1-methylguanine respectively by database search in METLIN. MS/MS spectra of 
7-methylguanine (Figure 5A) and 1-methylguanine (Figure 5B) showed the major fragmentation peak 
at m/z 149, which was a result of the loss of an amino group at the C-2 position of the guanine group. 
Another peak at m/z 124 in the MS/MS spectra of 7-methylguanine was formed by losing the N-1,  
N-9 and C-8 position of 7-methylguanine, whereas the peak at m/z 135 in the MS/MS spectra of  
1-methylguanine represent the loss of methyl group at N-1 position and amino group at C-2 position 
from 1-methylguanine. Among all the six Aspergillus species, 7-methylguanine and 1-methylguanine 
were both expressed in highest abundance in A. fumigatus and lowest abundance in A. terreus. 
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Figure 5. MS/MS spectra of (A) 7-methylguanine; (B) 1-methylguanine; (C) Leu–Glu–Leu–Glu; 
(D) (sulfooxy)benzoic acid and (E) hydroxyl(sulfooxy)benzoic acid. 
The metabolite (compound 5 in Table 1) with [M + H]+ of m/z 503.2749, at a retention time of 9.98 min, 
and molecular formula of C22H38N4O9 matched 24 tetra-peptides by database search in METLIN. The peptide 
sequence was revealed to be Leu–Glu–Leu–Glu by using Peaks©7 (Bioinformatics Solution Inc., Waterloo, 
ON, Canada). Different peaks in the MS/MS spectrum of the tetra-peptide represented different 
fragmented peptide ions (m/z = 96, b1-H2O ion; m/z = 114, b1 ion, m/z = 131, y1-NH3 ion; m/z = 225, 
b2-H2O ion; m/z = 243, y2-H2O and/or b2 ions and m/z = 261, y2 ion) (Figure 5C). Among all the 
Aspergillus species, Leu–Glu–Leu–Glu was expressed in highest abundance in A. flavus and lowest 
abundance in A. terreus. 
Two metabolites (compounds 3 and 4 in Table 1), with undefined positional isomers, were 
identified by exact molecular weight, predicted molecular formula, MS/MS fragmentation pattern and 
literature search. Compound 4 in Table 1, with deprotonated molecular ion at m/z 216.9822 and at  
a retention time of 6.80 min, was identified as C7H6O6S. The MS/MS fragmentation pattern (Figure 5D) 
supported that the chemical structure of compound 4 is (sulfooxy)benzoic acid. The peak at m/z 173 
referred to the loss of carboxylic acid from the parent ion. The peak at m/z 137 represented the ion of 
hydroxybenzoic acid, which was formed by losing a sulfoxy group at the o-position of the phenol 
group from the parent ion. A further loss of a carboxylic acid group yielded a phenol ion with m/z 93. 
Based on the predicted molecular formula and the MS/MS fragmentation of compound 4, we concluded 
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that compound 4 is either 4-(sulfooxy)benzoic acid or its positional isomers (o-positional isomer,  
2-(sulfooxy)benzoic acid; p-positional isomer, 3-(sulfooxy)benzoic acid). Another metabolite, 
compound 3, with deprotonated molecular ion at m/z 232.9775 and at a retention time of 6.20 min,  
was identified as C7H6O7S. The MS/MS fragmentation pattern (Figure 5E) supported that the chemical 
structure of compound 3 is hydroxyl-(sufooxy)benzoic acid. The peak at m/z 189 referred to the loss of 
carboxylic acid from the parent ion. The peak at m/z 153 represented the ion of dihydroxybenzoic acid, 
which was formed by losing a sulfoxy group at the o-position of the hydroxyphenol group from the 
parent ion. A further loss of a carboxylic acid group yielded a benzene-diol ion with m/z 109. 
The metabolite (compound 6 in Table 1), with [M + H]+ of m/z 292.2645, at a retention time of 19.55 min, 
and with molecular formula C19H33NO, matched 17β-amino-5α-androstan-11β-ol by database search  
in METLIN. However, the MS/MS fragmentation pattern was not compatible with the chemical 
structure of the matched compound (Figure A1). Similar discrepancies between the matched compound 
by database search and MS/MS fragmentation patterns were also observed in another two metabolites, 
compounds 7 and 8 in Table 1. These two metabolites, at retention time of 28.5 and 28.8 min, with the 
same [M + H]+ of m/z 352.2466 and molecular formula of C20H33NO4, were both matched to N-3-oxo-
hexadec-11(Z)-enoyl-L-Homoserine lactone by database search in METLIN. However, the MS/MS 
fragmentation patterns of these two metabolites were not compatible with the chemical structures of 
the matched compounds (Figure A1). Since compound 7 and compound 8 had the same molecular 
formula, as well as their similar retention times and MS/MS spectra, these two compounds were 
proposed to be diastereomers. Compounds 6–8 listed in Table 1 are the potentially novel metabolites. 
3. Discussion 
In this study, by comparing the metabolomic profiles of the six Aspergillus species and 10 non-Aspergillus 
fungal species, we identified at least eight Aspergillus species-specific compounds in Aspergillus 
culture supernatants. The six Aspergillus species used were the four most commonly used Aspergillus 
species encountered in clinical specimens, including A. fumigatus, A. flavus, A. niger and A. terreus,  
as well as A. nomius and A. tamarii, two Aspergillus species commonly misidentified as A. flavus [17]. 
The control non-Aspergillus fungal species include commonly encountered yeasts (Candida albicans 
and Cryptococcus neoformans), molds (Monascus pilosus, Phaeoacremonium parasiticum, 
Trichophyton rubrum, Trichophyton interdigitale and Lichtheimia species) and thermal dimorphic 
fungus in our locality (P. marneffei). Multivariate analyses by unsupervised PCA and supervised PLS-DA 
showed that the Aspergillus species and non-Aspergillus species were clustered separately into two groups, 
indicating that there were potential metabolite(s) that could be used to differentiate them (Figures 2 and 3). 
Subsequent extraction, statistical analysis and manual verification of the MFs revealed eight compounds 
that could be detected in the culture supernatants of all the six Aspergillus species but none of the other 
control fungal species. Since both the Aspergillus and non-Aspergillus species were cultured in the 
same culture medium, these compounds were genuine metabolites of the Aspergillus species.  
These Aspergillus specific fungal compounds and/or their metabolites may represent specific 
molecules that can be potentially detected in serum and/or urine of patients with invasive aspergillosis. 
Further studies using serum and urine samples of patients with culture and histology documented 
Int. J. Mol. Sci. 2015, 16 13859 
 
 
invasive aspergillosis should be performed to investigate which of these compounds and/or their 
metabolites could be detected in patients with aspergillosis for use in clinical microbiology laboratories. 
One of the eight metabolites, compound 5 (Leu–Glu–Leu–Glu), observed in the six pathogenic 
Aspergillus species but not in other fungi, is a novel tetrapeptide specific to the Aspergillus species. 
Tetrapeptides are ribosomally or non-ribosomally synthesized secondary metabolites with biological 
functions. Ribosomally synthesized tetrapeptides are synthesized by ribosomal peptide synthetic 
(RiPS) pathway, whereas non-ribosomally synthesized tetrapeptides are synthesized by non-ribosomal 
peptide synthase (NRPS) gene clusters. Structurally, tetrapeptides can be linear or cyclic. In Aspergillus 
species, only two tetrapeptides are known (Table 2). The first one is ustiloxin B, a ribosomally 
synthesized cyclic tetrapeptide with sequence Tyr–Ala–Ile–Gly, the tyrosine residue of which is 
modified with norvaline, found in A. flavus [21]. The other one is asperterrestide A, a cyclic 
tetrapeptide with sequence anthranilic acid-3-OH-N-Me-Phe–Ile–Ala, found in A. terreus [22].  
The tetrapeptide Leu–Glu–Leu–Glu discovered in the present study represents the first linear 
tetrapeptide observed in Aspergillus species, which we propose to be named aspergitide. We searched 
the genomes of A. fumigatus, A. flavus, A. niger and A. terreus but found no DNA sequence that 
potentially encodes repetitive Leu–Glu–Leu–Glu as observed in the ustiloxin B gene cluster in the  
A. flavus genome [21]. Therefore, we speculate that Leu–Glu–Leu–Glu is synthesized by NRPS cluster 
instead of RiPS pathway. Since the six Aspergillus species are members in the Fumigati, Flavi, Nigri 
and Terrei sections, Leu–Glu–Leu–Glu may be a tetrapeptide conserved across many sections in  
this genus; or alternatively, as the six Aspergillus species in this study are all pathogenic fungi,  
Leu–Glu–Leu–Glu could be a tetrapeptide with virulence properties. 
Table 2. Known tetrapeptides in Aspergillus species. 
Tetrapeptide Sequence Linear/Cyclic 
Ribosomally/ 
Non-Ribosomally 
Synthesized 
Aspergillus Species 
from Which 
Tetrapeptide Is Found 
Biological Properties 
Ustiloxin B [21] 
Tyr–Ala– 
Ile–Gly 
Cyclic 
Ribosomally 
synthesized 
A. flavus Mitotic inhibitor 
Asperterrestide 
A [22] 
a ABA–3-OH-N-
Me-Phe–Ile–Ala 
Cyclic Unknown A. terreus 
Inhibitory effects on 
influenza virus H1N1 and 
H3N2, cytotoxicity against 
human carcinoma cell lines 
Aspergitide 
Leu–Glu– 
Leu–Glu 
Linear Unknown 
A. flavus, A. niger,  
A. fumigatus, A. terreus, 
A. nomius, A. tamarii 
Unknown 
a ABA—Anthranilic acid. 
Two other metabolites, compound 3 [hydroxy-(sulfooxy)benzoic acid] and compound 4 
[(sulfooxy)benzoic acid)], specific to the Aspergillus species may possess anti-inflammatory 
properties. 2-(sulfooxy)benzoic acid possesses a structure similar to those of aspirin  
[2-(acetoxy)benzoic acid] and salicylic acid (2-hydroxybenzoic acid) (Figure 6), which are potent 
analgesics and anti-inflammatory agents used for decades for treatment of various inflammatory 
conditions through inhibition of cyclooxygenases (COXs). Notably, it has been shown by molecular 
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docking experiments, during the process of searching for analogues of gallic acid, a cyclooxygenase-2 
(COX-2) inhibitor screened from medicinal plant, that 3-hydroxy-4-(sulfooxy)benzoic acid could be  
a potent COX-2 inhibitor [23]. However, both (sulfooxy)benzoic acid and hydroxy-(sulfooxy)benzoic 
acid have never been found naturally. In the present study, we showed that both of these compounds 
could be found in the metabolomes of the six pathogenic Aspergillus species. Since it has previously 
been reported that o-hydroxybenzoic acid and p-hydroxybenzoic acid were fungal secondary 
metabolites [24], we speculate that (sulfooxy)benzoic acid was formed by o-sulfation of hydroxybenzoic acid 
and hydroxy-(sulfooxy)benzoic acid was in turn formed by further oxidation of (sulfooxy)benzoic acid 
in the Aspergillus species. Further experiments will reveal whether these two metabolites of the pathogenic 
Aspergillus species are their virulent factors through suppression of the host inflammatory response. 
O OH
O CH3
O
Salicylic acid 
O OH
O
S
O
O OH
2-(sulfooxy)benzoic acid 
O OH
OH
Aspirin  
Figure 6. Chemical structures of 2-(sulfooxy)benzoic acid, aspirin and salicylic acid. 
4. Materials and Methods 
4.1. Aspergillus Strains and Culture 
Thirty Aspergillus strains of A. fumigatus, A. flavus, A. niger, A. terreus, A. nomius and A. tamarii; 
and 34 non-Aspergillus fungal strains, belonging to C. neoformans, M. pilosus, C. albicans,  
P. parasiticum, P. marneffei, T. rubrum, T. interdigitale and Lichtheimia species, were included in  
this study (Table 3). All clinical isolates were identified by standard phenotypic tests [25]. In addition, 
the identities of the Aspergillus strains were confirmed by ITS, β-tubulin and calmodulin gene 
sequencing [17]; M. pilosus and Trichophyton species were confirmed by ITS gene sequencing;  
P. parasiticum was confirmed by ITS and β-tubulin gene sequencing [26]; and those of the 
Lichtheimia species were confirmed by ITS, β-actin, EF1α and 28S rRNA gene sequencing [27,28]. 
All fungal strains were grown at a concentration of 2 × 106 CFU in 10 mL RPMI 1640 medium (Gibco, 
Grand Island, NY, USA) supplemented with 2% glucose with shaking at 250 rpm. Strains were cultured 
for 48 h at 37 °C for Aspergillus species, C. neoformans, M. pilosus, C. albicans, P. parasiticum and 
Lichtheimia species, 108 h at 37 °C for T. rubrum and yeast form of P. marneffei and 108 h at 25 °C  
for mold form of P. marneffei to reach their early stationary phases to achieve comparable fungal 
concentrations. The culture supernatant was filtered using 0.22-μm MCE filter (Millipore, Billerica, 
MA, USA) and quenched immediately in liquid nitrogen for 10 min. The filtrates were lyophilized and 
stored at −80 °C until sample extraction and analysis. Uninoculated culture medium was used as a negative 
control. All strains were grown in duplicates. 
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Table 3. Fungal strains used in this study. 
Fungal Species Strains Source of Strains 
Aspergillus fumigatus AF293, QC5096, PW1353, PW1354, PW1355, 
PW3460, PW3461, PW3462 
AF293, purchased from a FGSC; QC5096, QC 
strain (specimen 5096) from b UKNEQAS; 
others, clinical isolates from Hong Kong 
Aspergillus flavus ATCC204304, PW2952, PW2953, PW2954, 
PW2956, PW2957, PW2960, PW2961, PW2962 
ATCC204304, purchased from c ATCC; others, 
clinical isolates from Hong Kong [17] 
Aspergillus niger ATCC10577, PW3463, PW793, PW3464, 
PW3465 
ATCC10577, purchased from c ATCC; others, 
clinical isolates from Hong Kong 
Aspergillus terreus PW3466, PW3467, PW3468 Clinical isolates from Hong Kong 
Aspergillus nomius PW2955, PW2959, CBS260.88 CBS260.88, purchased from d CBS Fungal 
Biodiversity Centre; others, clinical isolates 
from Hong Kong [17] 
Aspergillus tamarii PW2958, CBS104.13 PW2958, clinical isolate from Hong Kong [17]; 
CBS104.13 purchased from d CBS Fungal 
Biodiversity Centre 
Trichophyton rubrum PW3469 Clinical isolate from Hong Kong 
Trichophyton interdigitale PW3470, PW3471 Clinical isolates from Hong Kong 
Cryptococcus neoformans CBS132, PW275 PW275, clinical isolate from Hong Kong; 
CBS132, purchased from d CBS Fungal 
Biodiversity Centre 
Monascus pilosus PW2536 Clinical isolate from Hong Kong 
Phaeoacremonium parasiticum PW2367, PW2483 Clinical isolates from Hong Kong [26] 
Candida albicans ATCC90028, PW904, PW905, PW906 ATCC90028, purchased from c ATCC; others, 
clinical isolates from Hong Kong 
Penicillium marneffei PM1, PM35, PM41 Clinical isolates from Hong Kong [29] 
Lichtheimia corymbifera PW1473, PW1449, PW1471, HKU25, PW1450, 
PW1472 
HKU25, QC strain (specimen 4727) from b 
UKNEQAS; others, clinical isolates from  
Hong Kong 
Lichtheimia ramosa PW2398, PW2399, HKU21, HKU22, HKU23, 
PW1493, PW1494, PW1495, PW1496 
HKU23, QC strain (specimen 8273) from b 
UKNEQAS; others, clinical isolates from  
Hong Kong [27] 
Lichtheimia hyalospora CBS173.67 Purchased from d CBS Fungal  
Biodiversity Centre 
a FGSC—Fungal Genetics Stock Centre; b UKNEQAS—United Kingdom National External Quality 
Assessment Service; c ATCC—American Type Culture Collection; d CBS—Centraal Bureau voor Schimmelcultures. 
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4.2. Chemicals and Reagents 
LC–MS grade water, methanol and acetonitrile were purchased from J.T. Baker (Center Valley, PA, 
USA). Formic Acid with ACS reagent grade was purchased from Sigma-Aldrich, Inc. (Saint Louis, 
MO, USA). 
4.3. Sample Preparation 
The samples were prepared according to our previous publications with minor modifications [17,19,30]. 
Lyophilized samples were reconstituted in 600 µL solvent mixture containing water/methanol/acetonitrile 
(2:4:4) (v/v/v). The sample mixtures were vortexed for 1 min followed by 10 min sonication at room 
temperature. After centrifugation at 14,000 rpm for 10 min at 4 °C, the supernatants were transferred to 
UHPLC–ESI-Q-TOF-MS analysis. To prevent batch effect, all specimens were analyzed in random manner. 
4.4. UHPLC–ESI-Q-TOF-MS Analysis 
UHPLC–ESI-Q-TOF-MS analysis was performed according to our previous publications with 
minor modifications [17,19,30]. For liquid chromatography, separations were performed using Agilent 
1290 Infinity UHPLC (Agilent Technologies, Waldronn, Germany) and Waters Acquity UPLC HSS T3 
(3.0 × 100 mm, 1.8 µm) column with Waters Acquity UPLC HSS T3 (2.1 × 5.0 mm, 1.8 µm) 
VanGuard Pre-column, The injection volume was 5 µL of each sample. The column and autosampler 
temperature were maintained at 45 and 15 °C respectively. Separation was performed at a flow rate of  
0.4 mL/min under a gradient program. Mobile phase A was 0.1% formic acid (v/v) in water. Mobile 
phase B was pure methanol. The gradient program was applied as follows: t = 0 min, 1% B; t = 2.0 min, 1% B; 
t = 12 min, 38% B; t = 30 min, 99.5% B; t = 35 min, 99.5% B; t = 35.1 min, 1% B; t = 38 min, 1% B. 
Mass spectrometry was operated in both positive and negative ESI mode using Agilent 6540  
Q-TOF mass spectrometer (Agilent Technologies, Santa Clara, CA, USA) with Agilent Jet Stream 
Electrospray ionization (ESI) source. The capillary voltage was kept at +3800 V with the nozzle 
voltage of +0 V in positive mode and −3500 V with the nozzle voltage of −0 V in negative mode. 
Other conditions were kept constant in all experiment. The gas temperature was kept at 320 °C.  
The drying gas (nitrogen) was set at 8 L/min. The pressure of the nebulizer gas (nitrogen) was 
maintained at 40 psi. The sheath gas was kept at a flow rate of 10 L/min at 380 °C. The voltages of the 
Fragmentor, Skimmer 1 and OctopoleRFPeak were kept at 135, 50 and 500 V, respectively. The scan 
range was adjusted to m/z 80–1700 at the acquisition rate of 2 spectra/s. Ultra-high purity nitrogen was 
used in product ion scanning (PIC) experiments. Product ion scanning was conducted using ultra-high 
purity nitrogen. MS/MS acquisition was operated in the same parameter as in MS acquisition. 
Collision Energy (CE) was set at 10, 20 or 40 eV for fragmentation of the targeted compounds to generate 
the best MS/MS spectra. 
4.5. Data Processing and Statistical Data Analysis 
The raw data from UHPLC–ESI-Q-TOF-MS and MS/MS were analyzed using Agilent Masshunter 
Qualitative Analysis software (version B.05.00, Agilent Technologies, Santa Clara, CA, USA). 
Multivariate analysis was used to examine the LC–MS data. Using molecular feature extraction (MFE) 
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algorithm for automated baseline correction, noise calculation, peak detection and chromatogram 
deconvolution, molecular features (MFs) characterized by retention time (RT), chromatographic peak 
intensity and accurate mass were obtained. Data were converted into compound exchange file format (.cef) 
and analyzed using Mass Profiler Professional (MPP) software package (version B.02.02, Agilent 
Technologies, Santa Clara, CA, USA) for data filtering, peak alignment and statistical analysis. For the 
data filtering process, MFs with abundance either lower than 8000 counts per second (cps) or less than 
two isobaric mass peaks were removed. Alignment of RT and m/z values was performed across the 
sample sets with a tolerance window of ±0.2 min and ±10 mDa respectively. Data were normalized and 
baseline transformation was performed according to the median expression level of all data. For biomarker 
discovery and noise reduction, MFs having more than 50% occurrence either in Aspergillus strains or 
in non-Aspergillus strains were included for statistical analysis. 
To identify the biomarkers in culture supernatant, univariate analysis was used. One-way analysis of 
variance (ANOVA) with Tukey’s post-hoc test was used to identify statistical significant biomarkers 
specifically present in the Aspergillus strains but not in non-Aspergillus fungal strains, where p-value <0.01 
and fold-change >16 were considered as statistically significant. MFs were further filtered using Volcano 
Plot for Aspergillus and non-Aspergillus groups’ comparison. To reduce non-significant MFs, Student’s 
t-test with Benjamini-Hochberg correction was used, and MFs with p-value <0.01 were selected for 
further processing. MFs are sequentially filtered by fold-change (FC) analysis (FC > 16) to find MFs 
that have high abundance ratios between the two groups. 
Stepwise reduction of the data dimensionality was followed by multivariate statistical analysis for PCA. 
PCA was performed by unsupervised pattern recognition technique. MFs specific to the Aspergillus 
strains were extracted from the PCA loading plot. PLS-DA was performed by supervised algorithm for 
the identification of important variables with discriminative power to explore the structure of the data 
and construct classification models. Box-and-whisker plots were generated using Analyse-it (Analyse-it 
Software, Leeds, UK). Abundance of metabolites specific to the Aspergillus strains with p-values <0.01, 
calculated by student’s t-test, was re-extracted from the raw data files of all the samples to re-confirm 
the metabolites were unique to the Aspergillus strains. The unique MFs of Aspergillus species were 
further studied for putative identification. 
4.6. Metabolite Identification 
Accurate masses of the unique MFs in Apergillus group were selected for product ion scanning. 
MS/MS spectra of the potential biomarkers were processed using Agilent MassHunter Qualitative 
Analysis software (version B.05.00, Agilent Technologies, Santa Clara, CA, USA) to generate 
potential molecular formula, based on the accurate mass and isotopic pattern recognitions of their parent 
and fragment ions. All putative biomarkers were confirmed by matching METLIN database 
(http://metlin.scripps.edu/), Human Metabolome Database (HMDB) (http://www.hmdb.ca/), MassBank 
(http://www.massbank.jp/), E. coli Metabolome Database (ECMDB) (http://www.ecmdb.ca/), LipidMaps 
(http://www.lipidmaps.org/), and KEGG database (http://www.genome.jp/kegg) search using exact 
molecular weights or MS/MS fragmentation pattern data and literature search. Efforts were made to 
distinguish metabolites from the other isobaric compounds whenever possible by their elution order 
and virtue of difference in fragmentation pattern corresponding to their structural characteristics. 
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Appendix 
Table A1. Median of the relative abundance of metabolites produced in Aspergillus species. 
Metabolites A. flavus A. fumigatus A. niger A. nomius A. tamarii A. terreus 
7-Methylguanine 17.772 33.947 27.289 13.295 17.071 2.750 
1-Methylguanine 30.889 62.172 13.046 19.916 22.300 5.938 
Hydroxy(sulfooxy)benzoic acid 5.244 1.059 1.379 1.866 42.364 8.141 
(sulfooxy)benzoic acid 27.090 33.055 58.020 13.822 11.993 19.945 
Leu–Glu–Leu–Glu 64.978 1.332 7.029 38.083 11.068 0.0145 
Protonated molecular ion of m/z 292.3 9.885 4.691 25.409 5.392 18.912 15.520 
Protonated molecular ion of m/z 352.2 9.035 3.567 36.472 8.992 12.176 24.447 
Protonated molecular ion of m/z 352.2 3.965 2.126 11.142 4.273 5.556 9.046 
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Figure A1. MS/MS spectra of metabolites with protonated molecular ions with (A) m/z 
292.2645 eluted at 19.55 min; (B) m/z 352.2466 eluted at 28.5 min and (C) m/z 352.2466 
eluted at 28.8 min. 
References 
1. Latge, J.P. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 1999, 12, 310–350. 
2. Yuen, K.Y.; Chan, C.M.; Chan, K.M.; Woo, P.C.; Che, X.Y.; Leung, A.S.; Cao, L. 
Characterization of AFMP1: A novel target for serodiagnosis of aspergillosis. J. Clin. Microbiol. 
2001, 39, 3830–3837. 
3. Woo, P.C.; Chan, C.M.; Leung, A.S.; Lau, S.K.; Che, X.Y.; Wong, S.S.; Cao, L.; Yuen, K.Y. 
Detection of cell wall galactomannoprotein Afmp1p in culture supernatants of aspergillus 
fumigatus and in sera of aspergillosis patients. J. Clin. Microbiol. 2002, 40, 4382–4387. 
4. Woo, P.C.; Chong, K.T.; Leung, A.S.; Wong, S.S.; Lau, S.K.; Yuen, K.Y. Aflmp1 encodes an 
antigenic cell wall protein in Aspergillus flavus. J. Clin. Microbiol. 2003, 41, 845–850. 
5. Chong, K.T.; Woo, P.C.; Lau, S.K.; Huang, Y.; Yuen, K.Y. Afmp2 encodes a novel immunogenic 
protein of the antigenic mannoprotein superfamily in Aspergillus fumigatus. J. Clin. Microbiol. 
2004, 42, 2287–2291. 
6. Yuen, K.Y.; Woo, P.C.; Ip, M.S.; Liang, R.H.; Chiu, E.K.; Siau, H.; Ho, P.L.; Chen, F.F.; Chan, T.K. 
Stage-specific manifestation of mold infections in bone marrow transplant recipients: Risk factors 
and clinical significance of positive concentrated smears. Clin. Infect. Dis. 1997, 25, 37–42. 
7. Chan, C.M.; Woo, P.C.; Leung, A.S.; Lau, S.K.; Che, X.Y.; Cao, L.; Yuen, K.Y. Detection of 
antibodies specific to an antigenic cell wall galactomannoprotein for serodiagnosis of Aspergillus 
fumigatus aspergillosis. J. Clin. Microbiol. 2002, 40, 2041–2045. 
Int. J. Mol. Sci. 2015, 16 13866 
 
 
8. Barton, R.C. Laboratory diagnosis of invasive aspergillosis: From diagnosis to prediction of 
outcome. Scientifica 2013, 2013, 459405. 
9. Ruping, M.J.; Gerlach, S.; Fischer, G.; Lass-Florl, C.; Hellmich, M.; Vehreschild, J.J.; Cornely, O.A. 
Environmental and clinical epidemiology of Aspergillus terreus: Data from a prospective 
surveillance study. J. Hosp. Infect. 2011, 78, 226–230. 
10. Olivier, I.; Loots, D. An overview of tuberculosis treatments and diagnostics. What role could 
metabolomics play. J. Cell Tissue Res. 2011, 11, 2655–2671. 
11. Olivier, I.; Loots du, T. A metabolomics approach to characterise and identify various 
mycobacterium species. J. Microbiol. Methods 2012, 88, 419–426. 
12. Meissner-Roloff, R.J.; Koekemoer, G.; Warren, R.M. A metabolomics investigation of a hyper-and 
hypo-virulent phenotype of beijing lineage M. tuberculosis. Metabolomics 2012, 8, 1194–1203. 
13. Schoeman, J.C.; Loots, D.T. Improved disease characterisation and diagnostics using 
metabolomics: A review. J. Cell Tissue Res. 2011, 11, 2673–2683. 
14. Mahadevan, S.; Shah, S.L.; Marrie, T.J.; Slupsky, C.M. Analysis of metabolomic data using 
support vector machines. Anal. Chem. 2008, 80, 7562–7570. 
15. Van, Q.N.; Klose, J.R.; Lucas, D.A.; Prieto, D.A.; Luke, B.; Collins, J.; Burt, S.K.; Chmurny, G.N.; 
Issaq, H.J.; Conrads, T.P.; et al. The use of urine proteomic and metabonomic patterns for the 
diagnosis of interstitial cystitis and bacterial cystitis. Dis. Markers 2003, 19, 169–183. 
16. Lv, H.; Hung, C.S.; Chaturvedi, K.S.; Hooton, T.M.; Henderson, J.P. Development of an 
integrated metabolomic profiling approach for infectious diseases research. Analyst 2011, 136, 
4752–4763. 
17. Tam, E.W.; Chen, J.H.; Lau, E.C.; Ngan, A.H.; Fung, K.S.; Lee, K.C.; Lam, C.W.; Yuen, K.Y.; 
Lau, S.K.; Woo, P.C. Misidentification of Aspergillus nomius and Aspergillus tamarii as 
Aspergillus flavus: Characterization by internal transcribed spacer, beta-tubulin, and calmodulin 
gene sequencing, metabolic fingerprinting, and matrix-assisted laser desorption ionization-time of 
flight mass spectrometry. J. Clin. Microbiol. 2014, 52, 1153–1160. 
18. To, K.K.; Fung, A.M.; Teng, J.L.; Curreem, S.O.; Lee, K.C.; Yuen, K.Y.; Lam, C.W.; Lau, S.K.; 
Woo, P.C. Characterization of a tsukamurella pseudo-outbreak by phenotypic tests, 16s  
rRNA sequencing, pulsed-field gel electrophoresis, and metabolic footprinting. J. Clin. Microbiol. 
2013, 51, 334–338. 
19. Woo, P.C.; Lam, C.W.; Tam, E.W.; Leung, C.K.; Wong, S.S.; Lau, S.K.; Yuen, K.Y. First discovery 
of two polyketide synthase genes for mitorubrinic acid and mitorubrinol yellow pigment 
biosynthesis and implications in virulence of Penicillium marneffei. PLoS Negl. Trop. Dis.  
2012, 6, e1871. 
20. Lau, S.K.; Lam, C.-W.; Curreem, S.O.; Lee, K.-C.; Lau, C.C.; Chow, W.-N.; Ngan, A.H.; To, K.K.; 
Chan, J.F.; Hung, I.F.; et al. Identification of specific metabolites in culture supernatant  
of mycobacterium tuberculosis using metabolomics: Exploration of potential biomarkers.  
Emerg. Microbes Infect. 2015, 4, e6. 
21. Umemura, M.; Nagano, N.; Koike, H.; Kawano, J.; Ishii, T.; Miyamura, Y.; Kikuchi, M.; Tamano, K.; 
Yu, J.; Shin-ya, K.; et al. Characterization of the biosynthetic gene cluster for the ribosomally 
synthesized cyclic peptide ustiloxin B in Aspergillus flavus. Fungal Genet. Biol. 2014, 68, 23–30. 
Int. J. Mol. Sci. 2015, 16 13867 
 
 
22. He, F.; Bao, J.; Zhang, X.Y.; Tu, Z.C.; Shi, Y.M.; Qi, S.H. Asperterrestide A, a cytotoxic cyclic 
tetrapeptide from the marine-derived fungus Aspergillus terreus SCSGAF0162. J. Nat. Prod. 
2013, 76, 1182–1186. 
23. Amaravani, M.; Prasad, N.K.; Ramakrishna, V. COX-2 structural analysis and docking studies 
with gallic acid structural analogues. SpringerPlus 2012, 1, 58. 
24. Nielsen, K.F.; Smedsgaard, J. Fungal metabolite screening: Database of 474 mycotoxins and 
fungal metabolites for dereplication by standardised liquid chromatography–UV–mass spectrometry 
methodology. J. Chromatogr. A 2003, 1002, 111–136. 
25. Brandt, M.E.; Warnock, D.W. Taxonomy and classification of fungi. In Manual of Clinical 
Microbiology; Versalovic, J., Carroll, K., Funke, G., Jorgensen, J., Landry, M., Warnock, D., Eds.; 
ASM Press: Washington, DC, USA, 2011; Volume 2. 
26. To, K.K.; Lau, S.K.; Wu, A.K.; Lee, R.A.; Ngan, A.H.; Tsang, C.C.; Ling, I.W.; Yuen, K.Y.; 
Woo, P.C. Phaeoacremonium parasiticum invasive infections and airway colonization characterized 
by agar block smear and its and beta-tubulin gene sequencing. Diagn. Microbiol. Infect. Dis. 
2012, 74, 190–197. 
27. Woo, P.C.; Lau, S.K.; Ngan, A.H.; Tung, E.T.; Leung, S.Y.; To, K.K.; Cheng, V.C.; Yuen, K.Y. 
Lichtheimia hongkongensis sp. Nov., a novel lichtheimia spp. associated with rhinocerebral, 
gastrointestinal, and cutaneous mucormycosis. Diagn. Microbiol. Infect. Dis. 2010, 66, 274–284. 
28. Leung, S.Y.; Huang, Y.; Lau, S.K.; Woo, P.C. Complete mitochondrial genome sequence of 
lichtheimia ramosa (syn. Lichtheimia hongkongensis). Genome Announc. 2014, 2, e00644–00614. 
29. Woo, P.C.; Lau, C.C.; Chong, K.T.; Tse, H.; Tsang, D.N.; Lee, R.A.; Tse, C.W.; Que, T.L.; 
Chung, L.M.; Ngan, A.H.; et al. Mp1 homologue-based multilocus sequence system for typing  
the pathogenic fungus Penicillium marneffei: A novel approach using lineage-specific genes.  
J. Clin. Microbiol. 2007, 45, 3647–3654. 
30. Woo, P.C.; Lam, C.W.; Tam, E.W.; Lee, K.C.; Yung, K.K.; Leung, C.K.; Sze, K.H.; Lau, S.K.; 
Yuen, K.Y. The biosynthetic pathway for a thousand-year-old natural food colorant and citrinin in 
Penicillium marneffei. Sci. Rep. 2014, 4, 6728. 
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
 
